These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 20155428)

  • 1. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer.
    Jian G; Songwen Z; Ling Z; Qinfang D; Jie Z; Liang T; Caicun Z
    J Cancer Res Clin Oncol; 2010 Sep; 136(9):1341-7. PubMed ID: 20155428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.
    Shih JY; Gow CH; Yu CJ; Yang CH; Chang YL; Tsai MF; Hsu YC; Chen KY; Su WP; Yang PC
    Int J Cancer; 2006 Feb; 118(4):963-9. PubMed ID: 16152581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
    Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J
    J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
    Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
    Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
    Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
    Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.
    Zhou Q; Zhang XC; Chen ZH; Yin XL; Yang JJ; Xu CR; Yan HH; Chen HJ; Su J; Zhong WZ; Yang XN; An SJ; Wang BC; Huang YS; Wang Z; Wu YL
    J Clin Oncol; 2011 Aug; 29(24):3316-21. PubMed ID: 21788562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial.
    Lim SW; Park S; Kim Y; Cho JH; Park SE; Lee H; Kim HK; Kim SM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2018 Oct; 124():293-297. PubMed ID: 30268476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
    He C; Liu M; Zhou C; Zhang J; Ouyang M; Zhong N; Xu J
    Int J Cancer; 2009 Nov; 125(10):2393-9. PubMed ID: 19530244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis.
    Yoshimura A; Yamada T; Tsuji T; Hamashima R; Shiotsu S; Yuba T; Takumi C; Uchino J; Hiraoka N; Takayama K
    Thorac Cancer; 2019 Mar; 10(3):557-563. PubMed ID: 30672656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
    J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
    Taron M; Ichinose Y; Rosell R; Mok T; Massuti B; Zamora L; Mate JL; Manegold C; Ono M; Queralt C; Jahan T; Sanchez JJ; Sanchez-Ronco M; Hsue V; Jablons D; Sanchez JM; Moran T
    Clin Cancer Res; 2005 Aug; 11(16):5878-85. PubMed ID: 16115929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [EGFR gene mutation statuses in advanced non-small cell lung cancer patients and their influence on effect of gefitinib].
    Zhong W; Wang M; Li L; Xia Y; Chen M; Zhang L; Zhao J
    Zhongguo Fei Ai Za Zhi; 2012 Sep; 15(9):513-20. PubMed ID: 22989454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
    Shukuya T; Takahashi T; Kaira R; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Naito T; Kaira K; Murakami H; Endo M; Takahashi K; Yamamoto N
    Cancer Sci; 2011 May; 102(5):1032-7. PubMed ID: 21272159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).
    Tamura K; Okamoto I; Kashii T; Negoro S; Hirashima T; Kudoh S; Ichinose Y; Ebi N; Shibata K; Nishimura T; Katakami N; Sawa T; Shimizu E; Fukuoka J; Satoh T; Fukuoka M;
    Br J Cancer; 2008 Mar; 98(5):907-14. PubMed ID: 18283321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
    Asahina H; Yamazaki K; Kinoshita I; Sukoh N; Harada M; Yokouchi H; Ishida T; Ogura S; Kojima T; Okamoto Y; Fujita Y; Dosaka-Akita H; Isobe H; Nishimura M
    Br J Cancer; 2006 Oct; 95(8):998-1004. PubMed ID: 17047648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
    Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
    Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.
    Cortes-Funes H; Gomez C; Rosell R; Valero P; Garcia-Giron C; Velasco A; Izquierdo A; Diz P; Camps C; Castellanos D; Alberola V; Cardenal F; Gonzalez-Larriba JL; Vieitez JM; Maeztu I; Sanchez JJ; Queralt C; Mayo C; Mendez P; Moran T; Taron M
    Ann Oncol; 2005 Jul; 16(7):1081-6. PubMed ID: 15851406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
    Rizvi NA; Rusch V; Pao W; Chaft JE; Ladanyi M; Miller VA; Krug LM; Azzoli CG; Bains M; Downey R; Flores R; Park B; Singh B; Zakowski M; Heelan RT; Shen R; Kris MG
    Clin Cancer Res; 2011 May; 17(10):3500-6. PubMed ID: 21558399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.
    Wang MC; Wang CL; Chen TL; Chang JW; Lu JJ; Chang PY; Chiou CC
    Clin Chem Lab Med; 2017 Oct; 55(12):1979-1986. PubMed ID: 28787267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.
    Xu JM; Han Y; Duan HQ; Gao EM; Zhang Y; Liu XQ; Zhang JS; Toschi L; Galetta D; Azzariti A; Paradiso A
    J Cancer Res Clin Oncol; 2009 Jun; 135(6):771-82. PubMed ID: 19020901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.